Neumora Therapeutics (NMRA) to Release Earnings on Tuesday

Neumora Therapeutics (NASDAQ:NMRA) is set to post its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Neumora Therapeutics to post earnings of ($0.38) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Neumora Therapeutics Stock Up 4.0 %

NMRA stock opened at $13.54 on Monday. Neumora Therapeutics has a one year low of $8.33 and a one year high of $21.00. The company has a fifty day moving average price of $13.02 and a two-hundred day moving average price of $11.35.

Insider Transactions at Neumora Therapeutics

In other news, CFO Joshua Pinto sold 28,496 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $11.63, for a total value of $331,408.48. Following the completion of the transaction, the chief financial officer now owns 210,469 shares of the company’s stock, valued at $2,447,754.47. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Matthew K. Fust sold 14,049 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares in the company, valued at $342,303. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Joshua Pinto sold 28,496 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $11.63, for a total transaction of $331,408.48. Following the completion of the transaction, the chief financial officer now owns 210,469 shares in the company, valued at approximately $2,447,754.47. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 110,538 shares of company stock worth $1,390,513. Corporate insiders own 26.40% of the company’s stock.

Analysts Set New Price Targets

NMRA has been the topic of a number of research reports. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a research note on Friday, October 18th. Royal Bank of Canada restated an “outperform” rating and issued a $29.00 price target on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. HC Wainwright started coverage on shares of Neumora Therapeutics in a report on Tuesday, October 1st. They set a “buy” rating and a $30.00 price target for the company. Finally, JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Neumora Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $21.67.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.